Clinical trials: Targeted Therapy
Diabetes Mellitus Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOOY (NCT00494013)
- Testing
- Insulin Lispro Protamine Suspension, Detemir
- Where
- 56 sites in United States, Argentina and 7 more
- Volunteers
- 442 people
- Sponsor
- Eli Lilly and Company
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
CLL
Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia
Using phage libraries extensively pre-absorbed on a series of normal cell types, we will isolate phage specifically internalized by B-CLL cells from newly diagnosed and untreated CLL patients.
- Trial name
- NCT02828774
- Testing
- there will be no intervention.
- Volunteers
- 30 people
- Sponsor
- Assuta Medical Center
Metastatic Renal Cell Carcinoma
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on…
- Trial name
- SPAZO (NCT02282579)
- Testing
- Pazopanib
- Where
- 34 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Triple Negative Breast Cancer
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Phase I/II, multicenter, open-label, single-arm trial in triple-negative breast cancer patients under first-line neoadjuvant therapy with approved standard of care anti-PD-1 monoclonal antibody (PD-1 inhibitor)…
- Trial name
- NCT06631092
- Testing
- Oral DNA Vaccine
- Where
- 2 sites in Germany
- Volunteers
- 28 people
- Sponsor
- NEC Bio B.V
Brain Arteriovenous Malformations (AVMs)
Shh Signaling in Brain AVMs: Novel Player & Therapeutic Target
The present study, entitled "SHAM Study," is a prospective observational translational study aimed at investigating the molecular mechanisms underlying brain arteriovenous malformations (AVMs).
- Trial name
- SHAM (NCT07676721)
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
You are being asked to take part in this study because you have prostate cancer that has spread to other parts of the body. This is an investigational study. Prednisone is FDA-approved and commercially available.
- Trial name
- NCT01254864
- Testing
- Abiraterone Acetate, Prednisone, Sunitinib
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- M.D. Anderson Cancer Center
Biliary Tract Neoplasms
Personalized Medicine for Advanced Biliary Cancer Patients
The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
- Trial name
- SAFIR-ABC10 (NCT05615818)
- Testing
- Futibatinib, Ivosidenib, Zanidatamab
- Where
- 69 sites in Belgium, France and 1 more
- Volunteers
- 800 people
- Sponsor
- UNICANCER
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
Heart failure with preserved ejection fraction (HFpEF) accounts for over 50% of heart failure cases in the United States, affecting a primarily elderly population.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
- Trial name
- NCT01354613
- Testing
- Dobutamine, Amlodipine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Immunotherapy
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
This is an experimental study to evaluate the safety and efficacy of CAR T cells targeting CAIX in the treatment of advanced renal cancer.
- Trial name
- NCT04969354
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Colorectal Adenocarcinoma Metastatic to the Liver
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether HAI is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in conversional resection rates and survival compared…
- Trial name
- NCT03125161
- Testing
- HAI, chemotherapy ± target therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fudan University
Cystic Fibrosis, CFTR Gene Mutation
Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies
Cystic Fibrosis, an inherited autosomal recessive disease, arises from mutations in the CFTR gene. For intronic mutations affecting splicing events, oligonucleotides therapy has the potential to restore the production of the full…
- Trial name
- ONB-CFTR (NCT05100823)
- Testing
- Nasal cells sampling, Rectal biopsy sampling
- Where
- France
- Volunteers
- 16 people
- Sponsor
- University Hospital, Montpellier
Hypercholesterolemia
TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)
Background: This is a randomized controlled trial (RCT) of two novel behavioral interventions to enhance treatment adherence and improve low-density lipoprotein cholesterol (LDL) in diabetes.
- Trial name
- TACTICS (NCT01043354)
- Testing
- stage-matched intervention, framing effects intervention
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Narrows Institute for Biomedical Research
Non-small Cell Lung Carcinoma, Urothelial Carcinoma
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients.
- Conditions
- Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
- Trial name
- NCT02795156
- Testing
- Afatinib, Regorafenib, Cabozantinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
B-cell Non-Hodgkin's Lymphoma
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL.
- Trial name
- NCT05436223
- Testing
- Human CD19Targeted T Cells Injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Patient Compliance
Human Outreach to Improve Adherence With Scheduled Pain Clinic Appointments
Patients tend to miss their scheduled appointments in chronic pain clinics for unknown reasons. This study will test the hypothesis in a prospective pragmatic trial that a human telephone call in the primary language of the…
- Trial name
- NCT03101969
- Testing
- Call
- Where
- United States
- Volunteers
- 1,022 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Breast Cancer, Her 2 Positive Breast Cancer
Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease
The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings.
- Trial name
- PERTUREAL (NCT07542496)
- Where
- 2 sites in Algeria
- Volunteers
- 1,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie
Triple Negative Breast Cancer
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients
c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA) surveillance component and a therapeutic component.
- Trial name
- c-TRAK-TN (NCT03145961)
- Testing
- Pembrolizumab
- Where
- 17 sites in United Kingdom
- Volunteers
- 208 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Brain Injuries, Traumatic, Cerebrovascular Circulation
CPPopt Guided Therapy: Assessment of Target Effectiveness
Despite improvements in management, mortality in severe traumatic brain injury (TBI) remains 25% and only 40% of patients survive without major handicap.
- Conditions
- Brain Injuries, Traumatic, Cerebrovascular Circulation, Homeostasis
- Trial name
- COGITATE (NCT02982122)
- Testing
- For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
- Where
- 2 sites in Belgium, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Maastricht University Medical Center